6550--NOI SS: Cepheid GeneXpert Infinity 80-80 Sys. Reagents/Lease

The Department of Veterans Affairs awarded a sole-source, indefinite-delivery, indefinite-quantity contract to Cepheid for the lease, reagents, consumables, and OEM-authorized support of the GeneXpert Infinity 80-80 Molecular Diagnostic System at the Michael E. DeBakey VA Medical Center in Houston, Texas. The contract, designated as 36C25626D0035, has a total estimated value of $4,500,000 and spans five annual ordering periods from March 1, 2026, to February 28, 2031. The acquisition was justified under FAR 6.302-1 due to the proprietary nature of Cepheid’s reagents and system, which are essential for maintaining validated clinical diagnostic workflows and cannot be replicated by other vendors. The contract was issued through Network Contracting Office 16, based in Ridgeland, Mississippi, with the contracting specialist, Shasta Britt, serving as the primary point of contact. Performance is localized at the Houston facility, and the system is critical for high-throughput molecular testing in support of patient care. Payment is processed through the VA’s Network Contracting Office in Houston, with invoicing likely handled via WAWF, though explicit payment terms are not detailed. The NAICS code 325413 identifies the procurement within pharmaceutical and medicine manufacturing, and while the contract includes no set-aside provisions or socioeconomic certifications, Cepheid’s Unique Entity ID is listed as W6HQTMWB9Q28. Inspection and acceptance will occur at the delivery site in Houston, with compliance implied to follow clinical standards such as CLIA and FDA-cleared protocols, though no specific regulatory references are cited. No attachments, clause details, evaluation factors, packaging specifications, or special requirements were provided in the post-award notice, suggesting that the full contractual terms exist outside the publicly disclosed documentation.